Current Report Filing (8-k)
March 16 2023 - 08:51AM
Edgar (US Regulatory)
0000946644
false
0000946644
2023-03-15
2023-03-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
March
15, 2023
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-27072 |
|
52-0845822 |
(state
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2117
SW Highway 484, Ocala FL |
|
34473 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (352) 448-7797
AIM
Immunotech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
AIM |
|
NYSE
American |
Item
7.01. Regulation FD Disclosure.
On
March 16, 2023, AIM ImmunoTech Inc. (the “Company”) issued a press release related to a presentation about a recent manuscript
titled “Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of
action.” The manuscript was previously noted in the Company’s Form 8-K filed with the SEC on March 8, 2023. For more information,
please review the press release, a copy of which is attached hereto as Exhibit 99.1.
This
information, including Exhibit 99.1, referenced herein, is “furnished” and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only
be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933,
as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference
in such filing.
Cautionary
Statements
This
Current Report on Form 8-K including the press release attached hereto contain certain forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing
future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve
a number of risks and uncertainties. The results discussed in the manuscript referenced in the press release and other matters discussed
in the press release are subject to a number of unknowns including, but not limited to, that significant additional testing and trials
will be required to determine whether Ampligen will be an effective treatment for Ebola virus, comments and additional testing requested
by the FDA if and when the Company files the Investigational New Drug application (“NDA”) described in the press release
and whether the Company will be able to obtain a Tropical Disease Priority Review Voucher for the NDA. Among other things, for those
statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does
not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Two of the authors of the manuscript are officers or directors of the Company. The information found on the Company’s website is
not incorporated by reference into this press release and is included for reference purposes only.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AIM IMMUNOTECH INC. |
|
|
March 16, 2023 |
By: |
/s/ Thomas K. Equels |
|
|
Thomas K. Equels, CEO |
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Feb 2024 to Mar 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Mar 2023 to Mar 2024